Cwm LLC Sells 6,415 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Cwm LLC lessened its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 11.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 47,335 shares of the biotechnology company’s stock after selling 6,415 shares during the period. Cwm LLC’s holdings in BioCryst Pharmaceuticals were worth $424,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Bender Robert & Associates bought a new stake in BioCryst Pharmaceuticals during the second quarter valued at about $212,000. Assenagon Asset Management S.A. grew its holdings in BioCryst Pharmaceuticals by 25,631.2% during the second quarter. Assenagon Asset Management S.A. now owns 3,620,637 shares of the biotechnology company’s stock valued at $32,441,000 after purchasing an additional 3,606,566 shares during the period. Family Legacy Financial Solutions LLC bought a new stake in BioCryst Pharmaceuticals during the second quarter valued at about $72,000. Doliver Advisors LP grew its holdings in BioCryst Pharmaceuticals by 269.1% during the second quarter. Doliver Advisors LP now owns 274,328 shares of the biotechnology company’s stock valued at $2,458,000 after purchasing an additional 200,000 shares during the period. Finally, Rhumbline Advisers grew its holdings in BioCryst Pharmaceuticals by 3.9% during the first quarter. Rhumbline Advisers now owns 321,154 shares of the biotechnology company’s stock valued at $2,409,000 after purchasing an additional 12,022 shares during the period. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Up 0.1%

NASDAQ:BCRX opened at $7.20 on Friday. The company has a market capitalization of $1.51 billion, a P/E ratio of -40.00 and a beta of 1.05. BioCryst Pharmaceuticals, Inc. has a 12 month low of $6.00 and a 12 month high of $11.31. The business’s 50-day moving average is $7.70 and its 200 day moving average is $8.64.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to analysts’ expectations of $149.59 million. BioCryst Pharmaceuticals’s quarterly revenue was up 49.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.06) earnings per share. On average, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on BCRX. Wedbush boosted their price objective on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an “outperform” rating in a research report on Monday, June 30th. Wall Street Zen upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 26th. Weiss Ratings restated a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a research report on Friday. Cantor Fitzgerald boosted their price objective on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, October 15th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.18.

Insider Activity at BioCryst Pharmaceuticals

In related news, Director Theresa Heggie sold 70,000 shares of the business’s stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the sale, the director directly owned 65,352 shares in the company, valued at approximately $556,145.52. The trade was a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 5.10% of the company’s stock.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.